Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: linopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: linopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that linopril tablets be administered with a diuretic. acute myocardial infarction: linopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. linopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; iron oxide red - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: lisodrate tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: lisodrate tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisodrate tablets be administered with a diuretic. acute myocardial infarction: lisodrate tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisodrate tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; iron oxide red - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.